Business Description
![Corcept Therapeutics Inc Corcept Therapeutics Inc logo](https://static.gurufocus.com/logos/0C00000AQN.png?14)
Corcept Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US2183521028
Share Class Description:
FRA:HTD: Ordinary SharesDescription
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5404.75 | |||||
Equity-to-Asset | 0.84 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 21.87 | |||||
Beneish M-Score | -2.01 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.9 | |||||
3-Year EBITDA Growth Rate | -2.2 | |||||
3-Year EPS without NRI Growth Rate | 3.4 | |||||
3-Year FCF Growth Rate | -2.2 | |||||
3-Year Book Growth Rate | 3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 41.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 24.15 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.14 | |||||
9-Day RSI | 52.58 | |||||
14-Day RSI | 52.87 | |||||
6-1 Month Momentum % | 27.19 | |||||
12-1 Month Momentum % | 33.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.18 | |||||
Quick Ratio | 5.1 | |||||
Cash Ratio | 4.23 | |||||
Days Inventory | 342.06 | |||||
Days Sales Outstanding | 28.22 | |||||
Days Payable | 629.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 4 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 98.54 | |||||
Operating Margin % | 23.29 | |||||
Net Margin % | 22.54 | |||||
FCF Margin % | 23.95 | |||||
ROE % | 23.92 | |||||
ROA % | 19.58 | |||||
ROIC % | 69.46 | |||||
ROC (Joel Greenblatt) % | 22858.83 | |||||
ROCE % | 24.21 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 30.52 | |||||
Forward PE Ratio | 43.29 | |||||
PE Ratio without NRI | 30.52 | |||||
Shiller PE Ratio | 45.31 | |||||
Price-to-Owner-Earnings | 42.57 | |||||
PEG Ratio | 5.65 | |||||
PS Ratio | 6.82 | |||||
PB Ratio | 6.14 | |||||
Price-to-Tangible-Book | 6.14 | |||||
Price-to-Free-Cash-Flow | 28.6 | |||||
Price-to-Operating-Cash-Flow | 28.6 | |||||
EV-to-EBIT | 24.25 | |||||
EV-to-EBITDA | 23.92 | |||||
EV-to-Revenue | 5.65 | |||||
EV-to-Forward-Revenue | 4.62 | |||||
EV-to-FCF | 23.69 | |||||
Price-to-Projected-FCF | 1.46 | |||||
Price-to-Median-PS-Value | 0.81 | |||||
Price-to-Graham-Number | 2.88 | |||||
Price-to-Net-Current-Asset-Value | 8.51 | |||||
Price-to-Net-Cash | 11.11 | |||||
Earnings Yield (Greenblatt) % | 4.12 | |||||
FCF Yield % | 3.71 | |||||
Forward Rate of Return (Yacktman) % | 6.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Corcept Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 483.694 | ||
EPS (TTM) (€) | 0.98 | ||
Beta | 0.32 | ||
Volatility % | 68.01 | ||
14-Day RSI | 52.87 | ||
14-Day ATR (€) | 0.625314 | ||
20-Day SMA (€) | 28.133 | ||
12-1 Month Momentum % | 33.55 | ||
52-Week Range (€) | 19.4 - 31.62 | ||
Shares Outstanding (Mil) | 104.11 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Corcept Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Corcept Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Corcept Therapeutics Inc Frequently Asked Questions
What is Corcept Therapeutics Inc(FRA:HTD)'s stock price today?
The current price of FRA:HTD is €28.44. The 52 week high of FRA:HTD is €31.62 and 52 week low is €19.40.
When is next earnings date of Corcept Therapeutics Inc(FRA:HTD)?
The next earnings date of Corcept Therapeutics Inc(FRA:HTD) is 2024-08-02 Est..
Does Corcept Therapeutics Inc(FRA:HTD) pay dividends? If so, how much?
Corcept Therapeutics Inc(FRA:HTD) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |